Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Major News: Puruini® has been included in the 2025 National Reimbursement Drug List, marking a new era of universal access to treatment for drug-resistant tuberculosis.
Category:
Trade info
Author:
Source:
Add time:2026-04-13 10:25
On December 7, 2025, the “National Basic Medical Insurance, Maternity Insurance, and Work‑Injury Insurance Drug List (2025)” was officially released, and Puruini®—a novel anti‑tuberculosis medication developed by Shenyang Hongqi Pharmaceutical—was formally included in the national medical insurance scheme. This groundbreaking advancement enables patients with drug‑resistant tuberculosis to overcome the challenge of having access to effective treatment, ushering in a new era of therapy that is short‑course, highly efficacious, cost‑effective, and widely accessible.
• Treatment duration: Compared with the conventional 18–24-month regimen, the BPaL/BPaLM short-course regimen requires only 6 months and is entirely oral, with no injections.
• Efficacy: Cure rate exceeds 90%, median time to sputum conversion to negative is only 6 weeks, relapse rate is virtually zero, and the regimen is recommended as the first-line treatment in WHO guidelines.
• Price: Originally nearly RMB 90,000 for a 6-month course paid out-of-pocket; after insurance coverage, the patient’s out-of-pocket costs are significantly reduced, making it affordable for clinical patients.
• Mechanism: A triple‑action mechanism precisely targets drug‑resistant strains, exhibiting synergistic efficacy when combined with bedaquiline and linezolid.
As a company with 60 years of experience in combating tuberculosis, Shenyang Hongqi Pharmaceutical has not only expedited the rapid approval and market launch of Pto‑Mani but has also taken the lead in launching a public‑health assistance initiative—providing, in the first phase, medicines worth RMB 3 million free of charge at 18 hospitals across 12 provinces, ensuring that patients benefit immediately. By 2026, we will further expand our supply coverage, enabling designated tuberculosis treatment centers nationwide to offer the BPaL/BPaLM regimen, thereby supporting the public health goal of ending the tuberculosis epidemic.
With the implementation of medical insurance, we hope to move forward together! Let us jointly usher in a new era of universal access to treatment for drug‑resistant tuberculosis.
- END -
References:
1.N Engl J Med. 2020;382(10):893-902.
2. N Engl J Med. 2022 Sep 1;387(9)_810-823.
3.N Engl J Med. 2022 Dec 22;387(25):2331-2343.
4.https://iris.who.int/bitstream/handle/10665/378472/B09123-eng.pdf?sequence=1.
